MedTrace Logo

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

NCT04781686 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2021-05-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Apatinib plus Camrelizumab combined with docetaxel and S-1 as the first-line treatment of metastatic adenocarcinoma of gastric and gastroesophageal junction.

Conditions

  • Metastatic Gastric Adenocarcinoma
  • Metastatic Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Camrelizumab

Camrelizumab (200mg) will be given i.v. on day 1 of each 3-week cycle

DRUG

Apatinib Mesylate

Apatinib (250mg) will be administered orally once a day .

DRUG

S1

S1 (BSA\<1.25 40mg, BSA \>=1.25-\<1.5 50mg, BSA \>=1.5 60mg) will be administered orally twice daily on days 1-7 of each 3-week cycle

DRUG

Docetaxel injection

Docetaxel (75mg/m2 IV.drop) will be administered on day 1 of each 3-week cycle, for six cycles.

Sponsors & Collaborators

  • Hubei Cancer Hospital

    collaborator OTHER

  • Henan Provincial People's Hospital

    collaborator OTHER

  • Huangshi Central Hospital

    collaborator OTHER

  • Zhou Fuxiang

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-14
Primary Completion
2024-08-31
Completion
2025-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04781686 on ClinicalTrials.gov